2022 American Transplant Congress
Use of Belatacept in Non-Compliant Adolescent Patients
1Nemours Children's Health, Wilmington, DE, 2Nationwide Children's Hospital, Columbus, OH
*Purpose: Adolescents are at high risk for kidney transplant rejection due to non-compliance. While intravenous (IV) maintenance medications are FDA approved for adults, there is…2022 American Transplant Congress
Pd-1 Licenses Activated Treg for Lymphatic Migration
*Purpose: In addition to serving as fluid conduits, lymphatic vessels are critical portals for immune cell migration. Lymphatic endothelial cells (LECs) constitutively express high levels…2022 American Transplant Congress
An Additional Dose Of Viral Vector Covid-19 Vaccine And Mrna Covid-19 Vaccine In Kidney Transplant Recipients: A Randomized Controlled Trial
*Purpose: An additional dose of the COVID-19 vaccine following a primary series is recommended for solid organ transplant recipients. However, a comparison of the immunogenicity…2022 American Transplant Congress
Longitudinal Characterization of Memory B Cells During Antibody Mediated Rejection Treated with Plasmapheresis, Bortezomib, and Belatacept in Heart Transplant Recipients
*Purpose: Donor specific antibodies (DSA) and antibody mediated rejection (AMR) continue to limit allograft longevity after heart transplant. Effective treatments are limited and often complicated…2022 American Transplant Congress
Molecular Characterization of the Plasma Secretome in Pediatric Liver Transplantation (pLTx) Identified Cytokine/Chemokine Signatures Potentially Linked to Beneficial Immunosuppressive Regimes (IS) and Recovery
*Purpose: In the European multicentre “ChilSFree” study we aimed to characterize longitudinal dynamics of soluble immune mediators during the first year after pLTx.*Methods: Using Luminex-based…2022 American Transplant Congress
‘Adjuvant Conditioned’ Myeloid Derived Suppressor Cells Prolong Islets Graft Survival Through IL-10 Production
*Purpose: Advances in immunosuppression have been relatively stagnant over the last 2 decades and transplant patients continue to experience morbidity associated with immunosuppression regimens. Through…2022 American Transplant Congress
Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study
Paris Transplant Group, INSERM, Paris, France
*Purpose: Conversion to belatacept after transplant seems to be safe. However, no studies have reported the long-term efficacy and safety outcomes after conversion to belatacept…2022 American Transplant Congress
Managing Medications During a Pandemic: A Mixed-Methods Study of Perception of Adult Kidney Transplant Recipients and Those Waiting for a Kidney Transplant
*Purpose: Patients interact with healthcare providers (HCP) and pharmacists to manage medications. Little is known about the impact of COVID-19 on medication management. The purpose…2022 American Transplant Congress
Effect of Immunosuppression Withdrawal After Graft Failure on Re-Kidney Transplantation Outcomes
1Johns Hopkins University, Baltimore, MD, 2McGill University, Montreal, QC, Canada
*Purpose: The risk and benefit of immunosuppression use after graft failure need to be addressed to improve patient and graft survival after their re-kidney transplantation…2022 American Transplant Congress
Inflammation After Kidney Transplantation Is Associated With Overall- And Death-censored Graft Loss
Department of Transplantational Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway
*Purpose: Early graft loss after kidney transplantation (KT) is mainly a result of acute rejection, while long-term graft loss episodes are often dependent on multifactorial…
American Transplant Congress abstracts